MCID: SYS003
MIFTS: 49

Systolic Heart Failure

Categories: Cardiovascular diseases

Aliases & Classifications for Systolic Heart Failure

MalaCards integrated aliases for Systolic Heart Failure:

Name: Systolic Heart Failure 12 6 15 17
Heart Failure, Systolic 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9651
ICD9CM 34 428.2
MeSH 43 D054143
SNOMED-CT 67 417996009
ICD10 32 I50.20
UMLS 71 C1135191

Summaries for Systolic Heart Failure

MalaCards based summary : Systolic Heart Failure, also known as heart failure, systolic, is related to peripartum cardiomyopathy and left bundle branch hemiblock. An important gene associated with Systolic Heart Failure is NPPB (Natriuretic Peptide B), and among its related pathways/superpathways are Myometrial Relaxation and Contraction Pathways and MicroRNAs in cardiomyocyte hypertrophy. The drugs Metformin and Carvedilol have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and brain, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Systolic Heart Failure

Diseases related to Systolic Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 497)
# Related Disease Score Top Affiliating Genes
1 peripartum cardiomyopathy 32.5 TTN ADRB1 ACE
2 left bundle branch hemiblock 31.2 NR3C2 NPPB CRP ACE
3 mitral valve insufficiency 31.1 NR3C2 NPPB NPPA CRP ACE
4 atrioventricular block 30.9 TTN NPPB ACE
5 atrial standstill 1 30.9 TTN NPPB NPPA ADRB1 ACE
6 tricuspid valve insufficiency 30.9 NPPB EDN1 CRP ACE
7 myocarditis 30.8 TNF NPPB IL6 ACE
8 peripheral vascular disease 30.7 NOS3 IL6 CRP ACE
9 sexual disorder 30.6 NOS3 EDN1 ACE
10 chagas disease 30.6 TNF NPPB IL6 ADRB1 ACE
11 impotence 30.6 NOS3 EDN1 ACE
12 uremia 30.6 TNF IL6 CRP ACE
13 intermediate coronary syndrome 30.5 IL6 CRP ACE
14 intermittent claudication 30.5 IL6 CRP ACE
15 rheumatic heart disease 30.5 TNF NPPB IL6 ACE
16 congestive heart failure 30.4 TTN TNF NR3C2 NPPB NPPA NOS3
17 acute myocarditis 30.4 TNF NPPB CRP ACE
18 deficiency anemia 30.4 TNF NPPA IL6 CRP ACE
19 lipid metabolism disorder 30.3 IL6 CRP ADIPOQ ACE
20 pericardial effusion 30.3 NPPB NPPA IL6 CRP ACE
21 decubitus ulcer 30.3 TNF MMP9 IL6 CRP
22 gastroenteritis 30.3 TNF MMP9 IL6 CRP
23 nephrosclerosis 30.3 TNF NR3C2 ADRB1 ACE
24 central sleep apnea 30.1 NPPB NPPA NOS3 HSPB7 CRP ACE
25 aortic valve disease 2 30.1 TTN NPPB NPPA CRP ACE
26 arteries, anomalies of 30.1 TNF NOS3 IL6 EDN1 CRP ADIPOQ
27 anxiety 30.1 UCN TNF IL6 CRP ACE
28 pulmonary hypertension 30.1 TNF NPPB NPPA NOS3 IL6 EDN1
29 leptin deficiency or dysfunction 30.0 TNF IL6 CRP ADIPOQ
30 sleep apnea 30.0 TNF NPPB NOS3 IL6 EDN1 CRP
31 connective tissue disease 30.0 TNF IL6 EDN1 CRP ACE
32 diastolic heart failure 30.0 TTN NPPB NPPA NOS3 MMP9 MMP2
33 pulmonary disease, chronic obstructive 30.0 TTN TNF NPPB MMP9 IL6 CRP
34 heart valve disease 30.0 NR3C2 NPPB NPPA CRP ACE
35 coronary stenosis 30.0 NPPB IL6 CRP ADIPOQ ACE
36 sleep disorder 30.0 TNF IL6 EDN1 CRP ADIPOQ ACE
37 pheochromocytoma 29.9 TNF NPPA IL6 EDN1 ACE
38 hypothyroidism 29.9 TNF LGALS3 CST3 CRP ADIPOQ ACE
39 mitral valve disease 29.9 NPPB NPPA NOS3 CRP ACE
40 hypertensive heart disease 29.8 NR3C2 NPPB NPPA MMP9 MMP2 ACE
41 amyloidosis 29.8 TTN TNF NPPB IL6 CST3 CRP
42 lung disease 29.8 TNF NPPB MMP9 IL6 EDN1 CRP
43 atrial fibrillation 29.7 TTN NR3C2 NPPB NPPA NOS3 LGALS3
44 coronary heart disease 1 29.7 NPPB NOS3 IL6 EDN1 CRP ADIPOQ
45 lipoprotein quantitative trait locus 29.6 TNF NPPB NPPA NOS3 MMP9 IL6
46 respiratory failure 29.5 TTN TNF NPPB NPPA IL6 EDN1
47 angina pectoris 29.5 NPPB NOS3 IL6 EDN1 CRP ADRB1
48 pulmonary edema 29.5 TNF NR3C2 NPPB NPPA NOS3 EDN1
49 end stage renal disease 29.4 TNF NOS3 IL6 CST3 CRP ADIPOQ
50 apnea, obstructive sleep 29.2 TNF NPPB NOS3 IL6 EDN1 CRP

Graphical network of the top 20 diseases related to Systolic Heart Failure:



Diseases related to Systolic Heart Failure

Symptoms & Phenotypes for Systolic Heart Failure

MGI Mouse Phenotypes related to Systolic Heart Failure:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.43 ACE ADIPOQ ADRB1 CORIN CRP CST3
2 homeostasis/metabolism MP:0005376 10.41 ACE ADIPOQ ADRB1 CORIN CRP CST3
3 growth/size/body region MP:0005378 10.3 ACE ADIPOQ ADRB1 CORIN EDN1 HSPB7
4 behavior/neurological MP:0005386 10.27 ACE ADIPOQ GRK5 HSPB7 IL6 LGALS3
5 mortality/aging MP:0010768 10.25 ACE ADIPOQ ADRB1 CST3 EDN1 HSPB7
6 muscle MP:0005369 10.24 ADIPOQ ADRB1 CORIN CST3 EDN1 GRK5
7 adipose tissue MP:0005375 10.05 ACE ADIPOQ ADRB1 IL6 LGALS3 NOS3
8 nervous system MP:0003631 10.03 ADIPOQ CST3 EDN1 GRK5 IL6 LGALS3
9 neoplasm MP:0002006 9.92 ACE ADIPOQ CST3 IL6 LGALS3 MMP2
10 renal/urinary system MP:0005367 9.85 ACE ADIPOQ CORIN EDN1 IL6 LGALS3
11 respiratory system MP:0005388 9.61 ADIPOQ GRK5 HSPB7 IL6 LGALS3 MMP2
12 skeleton MP:0005390 9.32 ADIPOQ ADRB1 EDN1 IL6 LGALS3 MMP2

Drugs & Therapeutics for Systolic Heart Failure

Drugs for Systolic Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 157)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
3
Verapamil Approved Phase 4 52-53-9 2520
4
Lisinopril Approved, Investigational Phase 4 76547-98-3, 83915-83-7 5362119
5
Canagliflozin Approved Phase 4 842133-18-0
6
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
7
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
8
Enalaprilat Approved Phase 4 76420-72-9 6917719
9
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
10
Bisoprolol Approved Phase 4 66722-44-9 2405
11
Sodium citrate Approved, Investigational Phase 4 68-04-2
12
Atorvastatin Approved Phase 4 134523-00-5 60823
13
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
14
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
15
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
16
Hydralazine Approved Phase 4 86-54-4 3637
17
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
18
Eplerenone Approved Phase 4 107724-20-9 150310 443872
19
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
21
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
22
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
23
Simendan Investigational Phase 4 131741-08-7
24 Dipeptidyl-Peptidase IV Inhibitors Phase 4
25 Sodium-Glucose Transporter 2 Inhibitors Phase 4
26
protease inhibitors Phase 4
27 HIV Protease Inhibitors Phase 4
28 Sitagliptin Phosphate Phase 4
29 Incretins Phase 4
30 Phosphodiesterase 5 Inhibitors Phase 4
31 Adrenergic beta-1 Receptor Antagonists Phase 4
32 Adrenergic Antagonists Phase 4
33 Sympatholytics Phase 4
34 Natriuretic Peptide, Brain Phase 4
35 Purinergic P2Y Receptor Antagonists Phase 4
36 Platelet Aggregation Inhibitors Phase 4
37 Prasugrel hydrochloride Phase 4 389574-19-0
38 Trace Elements Phase 4
39 Micronutrients Phase 4
40 Vitamins Phase 4
41 Vitamin B Complex Phase 4
42 Lipid Regulating Agents Phase 4
43 Folate Phase 4
44 Nutrients Phase 4
45 Hypolipidemic Agents Phase 4
46 Vitamin B9 Phase 4
47 Citrate Phase 4
48 Sildenafil Citrate Phase 4 171599-83-0
49 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
50 Anticholesteremic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 242)
# Name Status NCT ID Phase Drugs
1 Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism Unknown status NCT02316743 Phase 4 Levothyroxine supplementation
2 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
3 A DANish Randomized, Controlled, Multicenter Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality. The DANISH Study Unknown status NCT00541268 Phase 4
4 Efficacy and Safety of Levothyroxine (L-T4) Replacement on Exercise Capability in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism: A 24-week, Multi-center, Open Label, Randomized, Parallel Group Trial Unknown status NCT03096613 Phase 4 Levothyroxine
5 Prophylactic Lisinopril to Prevent Anthracycline Induced Left Ventricular Systolic Dysfunction (PLAID) Study. Unknown status NCT03392740 Phase 4 Lisinopril;Placebo Oral Tablet
6 Metformin in Patients With Chronic and Acute Heart Failure: Pharmacokinetics and Polymorphisms in Genes Encoding Membrane Metformin Transporter Proteins Unknown status NCT02797340 Phase 4 Metformin
7 Inspiratory Muscle Training for Dyspneic Patients With COPD-HF Overlap: a Multicenter, Randomized Controlled Trial Unknown status NCT02579200 Phase 4
8 Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial Unknown status NCT01612260 Phase 4 Shensong Yangxin capsule;placebo Capsule
9 A Randomized Active-Control Double-Blinded Study to Evaluate the Treatment of Diabetes in Patients With Systolic Heart Failure Completed NCT02920918 Phase 4 Canagliflozin;Sitagliptin
10 Platelet Reactivity With Clopidogrel Versus Prasugrel in Patients With Systolic Heart Failure Completed NCT01765400 Phase 4 Prasugrel 10 mg daily x 2 weeks;Clopidogrel 75 mg daily x 2 weeks
11 A Randomized, Double-blind, Active-controlled Study to Assess the Effect of LCZ696 Compared With Enalapril to Improve Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF). Completed NCT02768298 Phase 4 LCZ696;enalapril;Enalapril matching placebo;LCZ696 matching placebo
12 SASHFR (South Asian Systolic Heart Failure Registry) : A Multi-center, Nonrandomized, Prospective Study to Collect Data Pertaining to the Demographic and Cardiovascular Profiles, Management Strategies and Clinical Outcomes of HF Patients. Completed NCT01434615 Phase 4
13 Dietary Nitrate Supplementation and Cardiorespiratory Control in Chronic Heart Failure: a Randomized, Placebo-controlled Trial Completed NCT02401126 Phase 4
14 Prospective, Open-labeled Trial in Patients With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea (PRISM) Completed NCT01074307 Phase 4 Low Dose Bisoprolol;High Dose Bisoprolol
15 Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure Completed NCT02903225 Phase 4
16 A Study Of The Usage Of Statins In A Community Heart Failure Population: The Impact of HMG Co-Enzyme A Reductase Inhibitors on Heart Structural Parameters, Brain Naturetic Peptide, Markers of Inflammation and Fibrosis Completed NCT00795912 Phase 4 Atorvastatin
17 Prospective, Multi-center, Open lAbel, Post-appRovAl Study AImed at Characterizing the Use of LCZ696 at 97 mg Sacubitril / 103 mg Valsartan Bid in Patients With HFrEF Completed NCT02690974 Phase 4 LCZ696 (sacubitril/valsartan)
18 A Randomized Controlled Trial of the Effect of Thiamin Supplementation on Heart Function in Ambulatory Patients With Heart Failure Completed NCT00959075 Phase 4
19 Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy Completed NCT01917149 Phase 4 Benazepril;Valsartan;Metoprolol
20 A Randomized, Double-blind, Placebo-controlled Study of the Effect of Mineralocorticoid Receptor Antagonists in Type 2 Diabetes Patients on Myocardial Function, Glucose and Fat Metabolism (The MIRAD-study) Completed NCT02809963 Phase 4 Eplerenone;Placebo
21 SIDAMI - Sildenafil and Diastolic Dysfunction After AMI Completed NCT01046838 Phase 4 Sildenafil;Placebo
22 Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality - FAIR-HF2 Recruiting NCT03036462 Phase 4 Iron;Saline
23 Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin. A Ringerike Heart Failure Cohort Phase IV Study of Angiotensin Receptor Neprilysin Inhibiton Recruiting NCT03553303 Phase 4 Sacubitril / Valsartan Oral Tablet
24 Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations Recruiting NCT03764722 Phase 4 Levosimendan
25 The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation Recruiting NCT04217135 Phase 4 evidence-based medications vs. high-dose hydralazine + evidence-based medications
26 Pulse Reduction On Beta-blocker and Ivabradine Therapy Recruiting NCT02973594 Phase 4 Ivabradine;Placebo
27 Cluster and Registry Trials Of the Working Group of Heart Failure in Denmark: Are SPironolactone and Eplerenone Comparable Treatments? Not yet recruiting NCT03984591 Phase 4 Eplerenone;Spironolactone
28 The Effect of Ferric Carboximaltose on Intra-myocardial Iron Load Assessed by Cardiac Magnetic Resonance in Patients With Heart Failure With Reduced Ejection Fraction (HFREF). Not yet recruiting NCT03871699 Phase 4 Ferric carboxymaltose
29 Effect of Servo-Ventilation on CO2 Regulation and Heart Rate Variability Not yet recruiting NCT03890939 Phase 4
30 Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure Reduced Ejection Fraction and Acute Decompensation With Low Cardiac Output: A Single Center, Randomized, Non-Blinded, and Parallel Study (PRIORITY-ADHF Study) Withdrawn NCT02767024 Phase 4 Sodium nitroprusside;Dobutamine;Furosemide
31 Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets (FIRST) Unknown status NCT02188082 Phase 2, Phase 3 IvabRadine hemisulfate Sustained-release Tablets;placebo
32 Impact of Renal Artery Denervation in Patients With Chronic Heart Failure Compared With Sham Procedure Unknown status NCT01639378 Phase 3
33 MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy Unknown status NCT01640769 Phase 3
34 Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure Unknown status NCT01913847 Phase 3 Sildenafil;Placebo
35 Intracoronary Infusion of BM-Derived Mononuclear Cells in Patients With Large Acute Myocardial Infarction Unknown status NCT00497211 Phase 2, Phase 3
36 Sildenafil in US Heart Failure Patients (SilHF-US) Unknown status NCT03460470 Phase 3 Sildenafil;Placebo oral capsule
37 Sildenafil in Heart Failure (SilHF); An Investigator Initiated Multinational Randomized Controlled Clinical Trial. Unknown status NCT01616381 Phase 3 Sildenafil;Placebo
38 The Effect of Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia Completed NCT02998697 Phase 2, Phase 3 Ferrous Sulfate;Placebo Oral Capsule
39 Spinal Cord Stimulation For Heart Failure As A Restorative Treatment Completed NCT01362725 Phase 2, Phase 3
40 Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure Completed NCT00206310 Phase 3 CRESTOR
41 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Hemodynamic and Clinical Effects of Natrecor (Nesiritide) Compared With Nitroglycerin Therapy for Symptomatic Decompensated CHF, The VMAC Trial: Vasodilation in the Management of Acute Congestive Heart Failure Completed NCT00270374 Phase 3 nesiritide
42 A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Effects of the Celacade™ System on Mortality and Morbidity in Patients With Chronic Heart Failure Completed NCT00111969 Phase 3
43 The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure Completed NCT00232180 Phase 3 Eplerenone
44 Thiamine Supplementation in Heart Failure Patients Receiving Full Medical Therapy Completed NCT01115504 Phase 3 Thiamine
45 Endothelin Receptor Blockade in Heart Failure With Diastolic Dysfunction and Pulmonary Hypertension Completed NCT00820352 Phase 3 bosentan;placebo
46 Growth Hormone Treatment in Patients With Ischemic Heart Failure and Circulating Levels of NT-proBNP Completed NCT04420481 Phase 3 Somatropin;Placebo
47 Aldosterone-blockade Randomized Controlled Trial In CHF - Diastolic Completed NCT00523757 Phase 3 Spironolactone;Placebo
48 Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients Completed NCT03662789 Phase 2, Phase 3 Iron Isomaltoside 1000
49 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Patients With Diabetes and Suspected or Known Coronary Artery Disease Completed NCT01754259 Phase 3 Ranolazine;Placebo
50 A Randomized, Double-blind, Active-controlled Study to Assess the Effect of Sacubitril/Valsartan Compared With Enalapril to Improve Erectile Function in Patients With Heart Failure With Reduced Ejection Fraction and Erectile Dysfunction Recruiting NCT03917459 Phase 3 LCZ696;Enalapril matching placebo;Enalapril;LCZ696 matching placebo

Search NIH Clinical Center for Systolic Heart Failure

Cochrane evidence based reviews: heart failure, systolic

Genetic Tests for Systolic Heart Failure

Anatomical Context for Systolic Heart Failure

MalaCards organs/tissues related to Systolic Heart Failure:

40
Heart, Testes, Brain, Kidney, Endothelial, Skeletal Muscle, Spinal Cord

Publications for Systolic Heart Failure

Articles related to Systolic Heart Failure:

(show top 50) (show all 2330)
# Title Authors PMID Year
1
Characterization of stressed transgenic mice overexpressing H2-histamine receptors in the heart. 61
32561687 2020
2
Expression of sex steroid receptors and aromatase in adipose tissue in different body regions in men with coronary artery disease with and without ischemic systolic heart failure. 61
30193537 2020
3
Unplanned Thirty-Day Readmission After Alcohol Septal Ablation for Hypertrophic Cardiomyopathy (From the Nationwide Readmission Database). 61
32305221 2020
4
The β-arrestin-biased β-adrenergic receptor blocker carvedilol enhances skeletal muscle contractility. 61
32414934 2020
5
Short-term efficacy and safety of levosimendan in patients with chronic systolic heart failure. 61
32555927 2020
6
Cardiac-peripheral transvenous gradients of microRNA expression in systolic heart failure patients. 61
32253819 2020
7
Average pixel intensity method for prediction of outcome in secondary mitral regurgitation. 61
32201372 2020
8
U-shaped association between plasma sphingosine-1-phosphate levels and mortality in patients with chronic systolic heart failure: a prospective cohort study. 61
32498720 2020
9
Neurohormonal Blockade During Left Ventricular Assist Device Support. 61
32433306 2020
10
Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions. 61
31199474 2020
11
Ventricular arrhythmias in heart failure with reduced ejection fraction. 61
32175938 2020
12
Pulmonary vascular resistance as a potential marker of reactive pulmonary hypertension reduction following sildenafil therapy in patients disqualified from orthotopic heart transplantation. 61
32454454 2020
13
Plasticity of cardiovascular chemoreflexes after prolonged unilateral carotid body denervation: implications for its therapeutic use. 61
32330089 2020
14
Population-Based Screening or Targeted Screening Based on Initial Clinical Risk Assessment for Atrial Fibrillation: A Report from the Huawei Heart Study. 61
32429241 2020
15
Publisher Correction: The Value of Cardiopulmonary Exercise Testing in Determining Severity in Patients with both Systolic Heart Failure and COPD. 61
32366922 2020
16
Clinical outcomes in patients with systolic heart failure. Are atrial high rate episodes a common marker of disease progression? 61
32380251 2020
17
Impact of Cardiac Resynchronization Therapy on Heart Transplant-Free Survival in Pediatric and Congenital Heart Disease Patients. 61
32202126 2020
18
Translational large animal model of hibernating myocardium: characterization by serial multimodal imaging. 61
32291522 2020
19
Infective Endocarditis Caused by Rhodococcus equi in an Immunocompetent Patient. 61
32467804 2020
20
Soluble ST2, Galectin-3 and clinical prognosis of patients with hypertrophic cardiomyopathy undergoing ventricular septal myectomy: a correlation analysis. 61
32420094 2020
21
Cost-effectiveness analysis of implantable cardiac devices in patients with systolic heart failure: a US perspective using real world data. 61
32207659 2020
22
Baseline and Exercise Predictors of V˙O2peak in Systolic Heart Failure Patients: Results from SMARTEX-HF. 61
31688648 2020
23
Quality of life and the associated risk of all-cause mortality in nonischemic heart failure. 61
32046910 2020
24
Mechanical Circulatory Support for Biventricular Heart Failure Using Advanced Ventricular Assist Device. 61
32465673 2020
25
Efficacy of Oral Iron Replacement Therapy in Pediatric Patients with Heart Failure. 61
32465778 2020
26
A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure. 61
32420983 2020
27
'Off-pump' left ventricular reconstruction - A causal and less invasive surgical option for patients with advanced systolic heart failure? 61
32086997 2020
28
The Heart Failure with Preserved Ejection Fraction Conundrum-Redefining the Problem and Finding Common Ground? 61
32112345 2020
29
Adaptive servo-ventilation therapy does not favourably alter sympatho-vagal balance in sleeping patients with systolic heart failure and central apnoeas: Preliminary data. 61
32317236 2020
30
Prevention and rescue of cardiac dysfunction by methanocarba adenosine monophosphonate derivatives. 61
31989534 2020
31
Liver-specific microRNA-122 as prognostic biomarker in patients with chronic systolic heart failure. 61
31757654 2020
32
Reversible Biventricular Heart Failure Due to Primary Adrenal Insufficiency. 61
32363353 2020
33
Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with non-ischemic systolic heart failure-DANISH-MRI. 61
31955812 2020
34
Baseline Right Ventricular Dysfunction Predicts Worse Outcomes in Patients Undergoing Cardiac Resynchronization Therapy Implantation. 61
31881279 2020
35
Association of serious adverse events with Cheyne-Stokes respiration characteristics in patients with systolic heart failure and central sleep apnoea: A SERVE-Heart Failure substudy analysis. 61
31218793 2020
36
APAP therapy does not improve impaired sleep quality and sympatho-vagal balance: a randomized trial in patients with obstructive sleep apnea and systolic heart failure. 61
31240541 2020
37
Effect of ferric-carboxy maltose on oxygen kinetics and functional status in heart failure patients with iron deficiency. 61
32518682 2020
38
Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. 61
31584516 2020
39
Percutaneous Intervention for Left Ventricular Assist Device Outflow Obstruction. 61
31530478 2020
40
Management of heart failure in patients with end-stage kidney disease on maintenance dialysis: a practical guide. 61
32259902 2020
41
The Value of Cardiopulmonary Exercise Testing in Determining Severity in Patients with both Systolic Heart Failure and COPD. 61
32152432 2020
42
Use of a Virtual Mock Loop model to evaluate a new left ventricular assist device for transapical insertion. 61
32089074 2020
43
Contemporary personalized β-blocker management in the perioperative setting. 61
31637510 2020
44
Safety of compression therapy for venous ulcer disease in the setting of congestive heart failure. 61
32028849 2020
45
Implications of Misclassification of Type 2 Myocardial Infarction on Clinical Outcomes. 61
31078438 2020
46
Synergistic prognostication of left ventricular hypertrophy and three-dimensional mechanical dyssynchrony in heart failure. 61
31965750 2020
47
Targeted and Controlled Drug Delivery to a Rat Model of Heart Failure Through a Magnetic Nanocomposite. 61
31696331 2020
48
Endothelial dysfunction and glycocalyx shedding in heart failure: insights from patients receiving cardiac resynchronisation therapy. 61
31455993 2020
49
The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure: Author's reply. 61
32031228 2020
50
Diagnostic and prognostic value of autoantibodies against β1-adrenoreceptors in patients with heart failure following acute myocardial infarction: A 5-year prospective study. 61
32010297 2020

Variations for Systolic Heart Failure

ClinVar genetic disease variations for Systolic Heart Failure:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ANKRD1 NM_014391.3(ANKRD1):c.827C>T (p.Ala276Val)SNV Conflicting interpretations of pathogenicity 45639 rs35550482 10:92675322-92675322 10:90915565-90915565
2 TTN NM_001267550.2(TTN):c.5668C>T (p.Arg1890Cys)SNV Conflicting interpretations of pathogenicity 47210 rs146496197 2:179640923-179640923 2:178776196-178776196
3 DSG2 NM_001943.5(DSG2):c.1543G>A (p.Val515Ile)SNV Benign/Likely benign 36010 rs2230235 18:29116284-29116284 18:31536321-31536321
4 DSP NM_004415.4(DSP):c.8300C>A (p.Thr2767Asn)SNV Benign/Likely benign 44963 rs34884895 6:7585795-7585795 6:7585562-7585562
5 DTNA NM_032978.7(DTNA):c.1348C>A (p.Pro450Thr)SNV Benign 46411 rs77320474 18:32431798-32431798 18:34851834-34851834

Expression for Systolic Heart Failure

Search GEO for disease gene expression data for Systolic Heart Failure.

Pathways for Systolic Heart Failure

Pathways related to Systolic Heart Failure according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.49 NOS3 IL6 GRK5 CORIN ADRB1
2
Show member pathways
12.11 TNF NPPB NPPA EDN1
3 12.05 TNF MMP9 MMP2 IL6 GRK5
4 11.96 TNF MMP9 LGALS3 IL6
5 11.94 TNF NOS3 MMP9 MMP2 EDN1
6 11.93 TNF MMP9 MMP2 IL6
7 11.91 TNF MMP9 IL6 EDN1
8
Show member pathways
11.9 TTN TNF IL6 EDN1 ADRB1 ACE
9 11.89 NPPA NOS3 IL6 EDN1
10
Show member pathways
11.71 NR3C2 NOS3 ACE
11 11.65 TNF NOS3 MMP2 IL6 EDN1
12 11.63 NPPA EDN1 ADRB1 ACE
13 11.61 MMP9 MMP2 IL6
14 11.6 NOS3 MMP9 MMP2 LGALS3
15
Show member pathways
11.56 TNF MMP9 MMP2 IL6
16 11.5 TNF MMP2 IL6
17 11.35 TNF NPPA IL6
18 11.35 TNF MMP9 MMP2 IL6
19 11.3 NOS3 EDN1 ADRB1
20 11.27 MMP9 MMP2 ACE
21 11.15 NOS3 MMP9 MMP2 IL6
22 11.13 NOS3 MMP9 MMP2
23 11.04 TNF IL6 ADIPOQ
24 10.97 TNF IL6 CRP
25 10.82 TNF MMP9 MMP2 IL6 EDN1
26 10.62 MMP9 MMP2 CST3 ACE

GO Terms for Systolic Heart Failure

Cellular components related to Systolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 TNF NPPB NPPA MMP9 MMP2 LGALS3
2 collagen-containing extracellular matrix GO:0062023 9.55 NPPA MMP9 MMP2 LGALS3 ADIPOQ
3 extracellular region GO:0005576 9.5 UCN TTN TNF NPPB NPPA MMP9

Biological processes related to Systolic Heart Failure according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.93 UCN TTN TNF NOS3 IL6 CRP
2 cellular protein metabolic process GO:0044267 9.89 NPPA MMP2 IL6 CST3
3 positive regulation of protein phosphorylation GO:0001934 9.86 UCN TNF MMP9 ADIPOQ
4 response to hypoxia GO:0001666 9.77 NPPA MMP2 EDN1 CST3 ADIPOQ
5 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.74 TNF NR3C2 EDN1
6 positive regulation of interleukin-6 production GO:0032755 9.72 UCN TNF IL6
7 response to glucocorticoid GO:0051384 9.71 UCN TNF IL6 ADIPOQ
8 negative regulation of fat cell differentiation GO:0045599 9.69 TNF IL6 ADIPOQ
9 embryo implantation GO:0007566 9.67 MMP9 MMP2 CST3
10 negative regulation of blood pressure GO:0045776 9.65 UCN NOS3 ADIPOQ
11 regulation of neuroinflammatory response GO:0150077 9.62 MMP9 IL6
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.62 TNF MMP2 IL6 EDN1
13 positive regulation of cardiac muscle contraction GO:0060452 9.61 UCN NPPA
14 cGMP biosynthetic process GO:0006182 9.61 NPPB NPPA
15 regulation of blood vessel diameter GO:0097746 9.61 NPPB NOS3 ACE
16 receptor guanylyl cyclase signaling pathway GO:0007168 9.6 NPPB NPPA
17 body fluid secretion GO:0007589 9.58 NPPB EDN1
18 neutrophil mediated immunity GO:0002446 9.58 IL6 ACE
19 positive regulation of mononuclear cell migration GO:0071677 9.54 TNF LGALS3
20 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.52 NOS3 EDN1
21 negative regulation of hormone secretion GO:0046888 9.43 UCN EDN1 ADIPOQ
22 negative regulation of lipid storage GO:0010888 9.33 TNF IL6 CRP
23 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.26 TNF MMP9 MMP2 EDN1
24 regulation of blood pressure GO:0008217 9.1 NPPB NPPA NOS3 EDN1 CORIN ACE

Molecular functions related to Systolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.13 UCN TTN TNF NR3C2 NPPB NPPA
2 cytokine activity GO:0005125 9.62 TNF IL6 EDN1 ADIPOQ
3 hormone receptor binding GO:0051427 9.26 NPPB NPPA
4 endopeptidase activity GO:0004175 9.26 MMP9 MMP2 CORIN ACE
5 hormone activity GO:0005179 9.02 UCN NPPB NPPA EDN1 ADIPOQ

Sources for Systolic Heart Failure

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....